ReviewJournal of clinical and translational hepatology2022
Statin-induced Liver Injury Patterns: A Clinical Review.
Review in Journal of clinical and translational hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 73 citations in OpenAlex.
- Prospective study of patients with immune checkpoint inhibitor-induced hepatitis; characterization of liver injury, outcome of therapy, and management of steroid-unresponsive and steroid-dependent hepatitis.Journal for immunotherapy of cancer · 2026Trial
- Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease.Scientific reports · 2026Trial
- Proteome-wide genetic analyses identify ASGR1 as a potential biomarker linking smoking with ischemic heart disease.Nature cardiovascular research · 2026Article
- Statin-Related Myotoxicity: A Narrative Review and Practical Approach for General Internists.Journal of general internal medicine · 2026Review
- A hierarchical risk assessment framework for head-to-head comparison of statin safety profiles in Chinese patients.Scientific reports · 2026Article
- Coenzyme Q10 protects against atorvastatin-induced hepatotoxicity via attenuation of oxidative stress and functional modulation of CYP3A1.BMC pharmacology & toxicology · 2026Article
- Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge.Fundamental & clinical pharmacology · 2026Article
- Prospective Open-Label Safety Study of Edaravone Dexborneol in Filipino Patients With Acute Ischemic Stroke.Brain and behavior · 2026Article
- Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses.European cardiology · 2026Review
- Borderline liver enzyme patterns and their metabolic-inflammatory signatures: an observational outpatient study.Frontiers in medicine · 2026Article
- Risk assessment of daikenchuto-induced hepatobiliary injury in colon cancer patients post-colectomy: a retrospective cohort study.BMC complementary medicine and therapies · 2025Article
- A prometabolite strategy inhibits cardiometabolic disease in an ApoE-/- murine model of atherosclerosis.JCI insight · 2025Article
- IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials.Drug safety · 2025Article
- Article
- Mini meta-analysis of anticholinesterase actions of atorvastatin, simvastatin and rosuvastatin, andToxicology reports · 2025Review
- Mechanisms of drug induced liver injury.Cellular and molecular life sciences : CMLS · 2025Review
- Article
- Lipid Metabolism: An Emerging Player in Sjögren's Syndrome.Clinical reviews in allergy & immunology · 2025Review
- Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins.Heliyon · 2025Review
- Hepatotoxicity associated with statins: A retrospective pharmacovigilance study based on the FAERS database.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since their introduction in 1987, hydroxymethyl glutaryl coenzyme A reductase (HMG-CoA) inhibitors, more commonly known as statins, have become some of the most widely prescribed medications in the world. Though generally considered to be safe and well tolerated, statins have been associated with several side effects including mild liver dysfunction manifested by increases in aminotransferases. Rarely, statins have been noted to induce more serious hepatic injury, including liver injury with autoimmune features. Current literature supports statin induced liver injury presenting in either hepatocellular or cholestatic patterns, though with the former being the prevailing pattern of injury. Fortunately, severe liver injury is uncommon with statin use and is generally reversible without any intervention other than offending statin cessation. When evaluating cases of suspected statin-induced liver injury, a complete medical history, laboratory tests including a complete metabolic panel, autoimmune markers, and viral panel, as well as hepatic imaging, are crucial for a complete causality analysis with validated tools such as Roussel Uclaf Causality Assessment Method. The aim of this review is to review the current evidence for statin-induced liver injury and cholestasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.